PNC Financial Services Group Inc. Has $1.14 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

PNC Financial Services Group Inc. grew its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 14.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,179 shares of the biotechnology company’s stock after acquiring an additional 412 shares during the quarter. PNC Financial Services Group Inc.’s holdings in United Therapeutics were worth $1,139,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Meiji Yasuda Asset Management Co Ltd. grew its position in United Therapeutics by 1.6% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after acquiring an additional 33 shares during the last quarter. Toronto Dominion Bank grew its holdings in shares of United Therapeutics by 0.8% during the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after purchasing an additional 37 shares during the last quarter. ClariVest Asset Management LLC grew its holdings in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of United Therapeutics by 14.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 42 shares during the period. Finally, First Citizens Bank & Trust Co. boosted its position in United Therapeutics by 1.8% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after buying an additional 48 shares during the period. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. TD Cowen raised their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Argus upped their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Wells Fargo & Company raised their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Finally, The Goldman Sachs Group upped their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Stock Up 0.3 %

United Therapeutics stock opened at $378.13 on Thursday. The company has a market capitalization of $16.88 billion, a PE ratio of 16.61, a PEG ratio of 1.07 and a beta of 0.56. The firm’s fifty day moving average is $366.18 and its 200 day moving average is $333.84. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the prior year, the firm earned $5.38 EPS. The business’s revenue was up 22.9% on a year-over-year basis. Sell-side analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Christopher Causey sold 510 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This trade represents a 12.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the sale, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at $947,597.55. This represents a 74.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 127,227 shares of company stock worth $47,398,820. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.